Soluble amyloid-β in the brain: The scarlet pimpernel

Journal of Alzheimer's Disease

Volumn 9, Issue SUPPL. 3, 2006, Pages 127-132

  Tabaton, Massimo ^a   Gambetti, Pierluigi ^b  

^a UNIVERSITY OF GENOA   (Italy)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN;

ALZHEIMER DISEASE; BRAIN TISSUE; DEGENERATIVE DISEASE; HUMAN; IMMUNOBLOTTING; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NEUROLOGIC DISEASE; NEUROPATHOLOGY; NEUROTOXICITY; PAIRED HELICAL FILAMENT; PHENOTYPE; PRION DISEASE; PRIORITY JOURNAL; PROTEIN ANALYSIS; REVIEW; SOLUBILITY;

EID: 84880187912     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/jad-2006-9s315     Document Type: Review

References (31)

1. M. Bucciantini, E. Giannoni, F. Chiti, F. Baroni, L. Formigli, J. Zurdo, N. Taddei, G. Ramponi, C.M. Dobson and M. Stefani, Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases, Nature 416 (2002), 507-511.
2. D.W. Dickson, H.A. Crystal, L.A. Mattiace, D.M. Masur, A.D. Blau, P. Davies, S.H. Yen and M.K. Aronson, Identification of normal and pathological aging in prospectively studied nondemented elderly humans, Neurobiol Aging 13 (1992), 179-189.
3. P. Gambetti, P. Parchi, S. Capellari, C. Russo, M. Tabaton, J.K. Teller and S.G. Chen, Mechanisms of phenotypic heterogeneity in prion, Alzheimer and other conformational diseases, J Alzheimers Dis 3 (2001), 87-95.
4. C.G. Glabe, Conformation-dependent antibodies target diseases of protein misfolding, Trends Biochem Sci 29 (2004), 542-547.
5. G.G. Glenner and C.W. Wong, Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein, Biochem Biophys Res Commun 120 (1984), 885-890.
6. A.M. Goate, A.R. Haynes, M.J. Owen, M. Farrall, L.A. James, L.Y. Lai, M.J. Mullan, P. Roques, M.N. Rossor, R. Williamson et al., Predisposing locus for Alzheimer's disease on chromosome 21, Lancet 1 (1989), 352-355.
7. C. Haass, M.G. Schlossmacher, A.Y. Hung, C. Vigo-Pelfrey, A. Mellon, B.L. Ostaszewski, I. Lieberburg, E.H. Koo, D. Schenk, D.B. Teplow et al., Amyloid beta-peptide is produced by cultured cells during normal metabolism, Nature 359 (1992), 322-325.
8. J.A. Hardy and G.A. Higgins, Alzheimer's disease: the amyloid cascade hypothesis, Science 256 (1992), 184-185.
9. J.T. Huse, K. Liu, D.S. Pijak, D. Carlin, V.M. Lee and R.W. Doms, Beta-secretase processing in the trans-Golgi network preferentially generates truncated amyloid species that accumulate in Alzheimer's disease brain, J Biol Chem 277 (2002), 16278-16284.
10. J. Kang, H.G. Lemaire, A. Unterbeck, J.M. Salbaum, C.L. Masters, K.H. Grzeschik, G. Multhaup, K. Beyreuther and B. Muller-Hill, The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor, Nature 325 (1987), 733-736.
11. T. Kawarabayashi, L.H. Younkin, T.C. Saido, M. Shoji, K.H. Ashe and S.G. Younkin, Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease, J Neurosci 21 (2001), 372-381.
12. H.A. Lashuel, D. Hartley, B.M. Petre, T. Walz and P.T. Lansbury, Jr., Neurodegenerative disease: amyloid pores from pathogenic mutations, Nature 418 (2002), 291.
13. C.L. Masters, G. Simms, N.A. Weinman, G. Multhaup, B.L. McDonald and K. Beyreuther, Amyloid plaque core protein in Alzheimer disease and Down syndrome, Proc Natl Acad Sci USA 82 (1985), 4245-4249.
14. H. Mori, K. Takio, M. Ogawara and D.J. Selkoe, Mass spectrometry of purified amyloid beta protein in Alzheimer's disease, J Biol Chem 267 (1992), 17082-17086.
15. A. Piccini, C. Russo, A. Gliozzi, A. Relini, A. Vitali, R. Borghi, L. Giliberto, A. Armirotti, C. D'Arrigo, A. Bachi, A. Cattaneo, C. Canale, S. Torrassa, T.C. Saido, W. Markesbery, P. Gambetti and M. Tabaton, Beta amyloid is different in normal aging and in Alzheimer's disease, J Biol Chem 280 (2005), 34186-34192.
16. M.B. Podlisny, B.L. Ostaszewski, S.L. Squazzo, E.H. Koo, R.E. Rydell, D.B. Teplow and D.J. Selkoe, Aggregation of secreted amyloid beta-protein into sodium dodecyl sulfate-stable oligomers in cell culture, J Biol Chem 270 (1995), 9564-9570.
17. C. Russo, T.C. Saido, L.M. DeBusk, M. Tabaton, P. Gambetti and J.K. Teller, Heterogeneity of water-soluble amyloid beta-peptide in Alzheimer's disease and Down's syndrome brains, FEBS Lett 409 (1997), 411-416.
18. C. Russo, G. Schettini, T.C. Saido, C. Hulette, C. Lippa, L. Lannfelt, B. Ghetti, P. Gambetti, M. Tabaton and J.K. Teller, Presenilin-1 mutations in Alzheimer's disease, Nature 405 (2000), 531-532.
19. N. Sergeant, S. Bombois, A. Ghestem, H. Drobecq, V. Kostanjevecki, C. Missiaen, A. Wattez, J.P. David, E. Vanmechelen, C. Sergheraert and A. Delacourte, Truncated beta-amyloid peptide species in pre-clinical Alzheimer's disease as new targets for the vaccination approach, J Neurochem 85 (2003), 1581-1591.
20. Y. Shinkai, M. Yoshimura, Y. Ito, A. Odaka, N. Suzuki, K. Yanagisawa and Y. Ihara, Amyloid beta-proteins 1-40 and 1-42(43) in the soluble fraction of extra- and intracranial blood vessels, Ann Neurol 38 (1995), 421-428.
21. M. Shoji, T.E. Golde, J. Ghiso, T.T. Cheung, S. Estus, L.M. Shaffer, X.D. Cai, D.M. McKay, R. Tintner, B. Frangione et al., Production of the Alzheimer amyloid beta protein by normal proteolytic processing, Science 258 (1992), 126-129.
22. M. Tabaton, M.G. Nunzi, R. Xue, M. Usiak, L. Autilio-Gambetti and P. Gambetti, Soluble amyloid beta-protein is a marker of Alzheimer amyloid in brain but not in cerebrospinal fluid, Biochem Biophys Res Commun 200 (1994), 1598-1603.
23. M. Tabaton and A. Piccini, Role of water-soluble amyloid-beta in the pathogenesis of Alzheimer's disease, Int J Exp Pathol 86 (2005), 139-145.
24. J.K. Teller, C. Russo, L.M. DeBusk, G. Angelini, D. Zaccheo, F. Dagna-Bricarelli, P. Scartezzini, S. Bertolini, D.M. Mann, M. Tabaton and P. Gambetti, Presence of soluble amyloid beta-peptide precedes amyloid plaque formation in Down's syndrome, Nat Med 2 (1996), 93-95.
25. R.D. Terry, N.K. Gonatas and M. Weiss, Ultrastructural Studies In Alzheimer's Presenile Dementia, Am J Pathol 44 (1964), 269-297.
26. D.M. Walsh, I. Klyubin, J.V. Fadeeva, W.K. Cullen, R. Anwyl, M.S. Wolfe, M.J. Rowan and D.J. Selkoe, Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo, Nature 416 (2002), 535-539.
27. D.M. Walsh, I. Klyubin, J.V. Fadeeva, M.J. Rowan and D.J. Selkoe, Amyloid-beta oligomers: their production, toxicity and therapeutic inhibition, Biochem Soc Trans 30 (2002), 552-557.
28. D.M. Walsh, B.P. Tseng, R.E. Rydel, M.B. Podlisny and D.J. Selkoe, The oligomerization of amyloid beta-protein begins intracellularly in cells derived from human brain, Biochemistry 39 (2000), 10831-10839.
29. J.S. Whitson, D.J. Selkoe and C.W. Cotman, Amyloid beta protein enhances the survival of hippocampal neurons in vitro, Science 243 (1989), 1488-1490.
30. H. Yamaguchi, S. Hirai, M. Morimatsu, M. Shoji and Y. Harigaya, Diffuse type of senile plaques in the brains of Alzheimer-type dementia, Acta Neuropathol (Berl) 77 (1988), 113-119.
31. B.A. Yankner, L.K. Duffy and D.A. Kirschner, Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides, Science 250 (1990), 279-282.